APG-2575
Phase 3Small molecule
Ascentage Pharma Group Inc.APG-2575 is one of 241 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
6
Indications
11
Total Trials
7
Active Trials
240
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
235 competitors in Acute Myeloid Leukemia
#DrugCompanyPhaseTrials
1Idamycin
PfizerPhase 3
Novantrone
PfizerPhase 3
Xospata
AstellasPhase 3
Vepesid
AAvyxa
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Mylotarg
WWyeth-Lederle Vaccines
Phase 3
Cerubidine
HHikma Pharmaceuticals LLC
Phase 3
Neupogen
EEastern Cooperative Oncology Group
Phase 3
Nexavar
BayerPhase 3
Cellcept
RochePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Multiple Myeloma2 trials
Hematologic Malignancies2 trials
Breast Cancer1 trial
Age1 trial
4 more indications
Relapsed/Refractory1 trial
Systemic Lupus Erythematosus1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for APG-2575. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company